Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Revenue (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Revenue data on record, last reported at $17.9 million in Q3 2025.

  • For Q3 2025, Revenue fell 0.6% year-over-year to $17.9 million; the TTM value through Sep 2025 reached $61.8 million, up 35.42%, while the annual FY2024 figure was $53.4 million, 18.47% down from the prior year.
  • Revenue reached $17.9 million in Q3 2025 per PLX's latest filing, up from $15.7 million in the prior quarter.
  • Across five years, Revenue topped out at $35.1 million in Q2 2023 and bottomed at $3.7 million in Q1 2024.
  • Average Revenue over 5 years is $13.1 million, with a median of $11.3 million recorded in 2021.
  • Peak YoY movement for Revenue: surged 300.72% in 2023, then plummeted 61.59% in 2024.
  • A 5-year view of Revenue shows it stood at $8.5 million in 2021, then grew by 0.8% to $8.6 million in 2022, then grew by 21.69% to $10.5 million in 2023, then skyrocketed by 73.74% to $18.2 million in 2024, then dropped by 2.01% to $17.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $17.9 million in Q3 2025, $15.7 million in Q2 2025, and $10.1 million in Q1 2025.